- Home
- EDSA vs ADTX Comparison
EDSA vs ADTX Comparison
Compare EDSA & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- ADTX
- Stock Information
- Founded
- EDSA 2015
- ADTX 2017
- Country
- EDSA Canada
- ADTX United States
- Employees
- EDSA N/A
- ADTX N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- ADTX Health Care
- Exchange
- EDSA Nasdaq
- ADTX Nasdaq
- Market Cap
- EDSA 6.2M
- ADTX 5.3M
- IPO Year
- EDSA N/A
- ADTX 2020
- Fundamental
- Price
- EDSA $2.36
- ADTX $2.30
- Analyst Decision
- EDSA Strong Buy
- ADTX
- Analyst Count
- EDSA 1
- ADTX 0
- Target Price
- EDSA $21.00
- ADTX N/A
- AVG Volume (30 Days)
- EDSA 8.9K
- ADTX 589.6K
- Earning Date
- EDSA 05-09-2025
- ADTX 05-19-2025
- Dividend Yield
- EDSA N/A
- ADTX N/A
- EPS Growth
- EDSA N/A
- ADTX N/A
- EPS
- EDSA N/A
- ADTX N/A
- Revenue
- EDSA N/A
- ADTX $133,985.00
- Revenue This Year
- EDSA N/A
- ADTX $15,768.94
- Revenue Next Year
- EDSA N/A
- ADTX N/A
- P/E Ratio
- EDSA N/A
- ADTX N/A
- Revenue Growth
- EDSA N/A
- ADTX N/A
- 52 Week Low
- EDSA $1.55
- ADTX $2.04
- 52 Week High
- EDSA $5.59
- ADTX $27,200.00
- Technical
- Relative Strength Index (RSI)
- EDSA 51.83
- ADTX 30.46
- Support Level
- EDSA $2.29
- ADTX $2.21
- Resistance Level
- EDSA $2.40
- ADTX $2.39
- Average True Range (ATR)
- EDSA 0.12
- ADTX 0.39
- MACD
- EDSA 0.00
- ADTX 0.49
- Stochastic Oscillator
- EDSA 87.88
- ADTX 11.11
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.